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Objective: This was a retrospective study of the efﬁcacy of urethral overdilation (UOD) for women with
voiding dysfunction.
Materials and methods: Thirty-six patients diagnosed with voiding dysfunction were enrolled. The main
indications for UOD included women with poor compliance (30 patients, 83.3%) and obstructive
symptoms with high residual urine (6 patients, 16.7%). We utilized a method called UOD (wide caliber),
dilating the urethra up to 54 Fr. Patients were re-evaluated every 3 months with serial free ﬂow rate and
ultrasound residual in the ﬁrst year and then as scheduled. Outcome measure was based on the change in
videourodynamic parameters, Urogenital Distress Inventory-6 (UDI-6) questionnaire, and International
Prostate Symptom Score (IPSS).
Results: Mean follow up period of 33.2 months (range: 13e61 months). Failure or success depended on
the change in videourodynamic parameters, UDI-6 score, and IPSS. The mean age with the Success Group
(n ¼ 22, 61.1%) and Failure Group (n ¼ 14, 39.3%) was 52.8 years and 54.1 years, respectively. Our data
showed signiﬁcant improvements in mean UDI-6 score and IPSS after treatment (11.5e5.7, p ¼ 0.032 and
14.8e5.2, p ¼ 0.006, respectively). By analyzing multiple parameters (age, parity, body mass index,
videourodynamics parameters, anesthesia bladder capacity, UDI-6 score, and IPSS) between the success
and failure groups, we found only anesthesia bladder capacity reached statistical signiﬁcance (536 mL vs.
418 mL, p ¼ 0.005).
Conclusion: The present study provides evidence that UOD, as a minimally invasive procedure, achieves a
satisfactory cure rate on short-term follow-up for women with voiding dysfunction.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Urethral dilation is not a new surgical technique and has been
used as an alternative treatment for voiding dysfunction for many
years. Previous reports cited applications in treating neurogenic
bladder [1], voiding dysfunction in women [2], and recurrent uri-
nary tract infections in children or management of high-risk mye-
lomeningocele [3,4]. However, among currently practicing
gynecologists this technique remains controversial [5e8] for
reasons ranging from change in indications to less-perceived
effectiveness.and Gynecology, Chang Gung
Chang Gung School of Medi-
iwan.
g).
bstetrics & Gynecology. PublishedAlso, controversies existed in this ﬁeld from lack of long-term
follow-up or well-controlled studies. Moreover, there is a lack of
uniformity about the size to which one dilates the urethra.
Urologists have tended to use either local anesthesia or nothing
when performing urethral dilation up to 26e36 Fr. Based on our
previous study (data unpublished), urethral overdilation (UOD)
improved voiding efﬁcacy, bladder compliance, and even relieved
storage symptoms. Therefore, we propose that effective dilation
can only be done under general anesthesia if the purpose of dilation
for womenwith voiding dysfunction is to alter the balance between
detrusor power and bladder outlet resistance, and that perhaps
dilating to 36 Fr is not sufﬁcient. We described a method called
UOD, which meant the urethra was dilated up to 54 Fr. The purpose
of this studywas to improve bladder emptying, bladder compliance
and, to a less extent, relieve storage symptoms. We reported our
experience using UOD for the management of womenwith voiding
dysfunction.by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic and clinical characteristics between groups.
Poor compliance,
n ¼ 30
Obstructive
symptoms,
n ¼ 6
Age (y) 53.1 ± 7.3 57.5 ± 6.3
Parity 2.7 ± 1.2 3.7 ± 1.4
Body mass index 24.9 ± 3.5 26 ± 3.7
History of RH (%) 14 (46.7)
Menopause 24/30 (60) 6 (100)
Etiology
Neurogenic DM 8 1
Stroke 2 1
Surgical RH 12 2
Hysterectomy 2
Continence procedure 1 1
Prolapse surgery 4
Idiopathic 1 1
Residual urine (mL) 111 ± 20.5 132 ± 15.7
End-ﬁlling pressure (cmH2O) 31.5 ± 9.4 7 ± 2.6
Max. cystometric capacity (mL) 351 ± 11.9 463 ± 14.7
Aesthesia bladder capacity (mL) 451 ± 34.7 625 ± 15.2
UDI-6 score 11.2 ± 3.5 12.3 ± 2.7
IPSS 14.2 ± 2.1 14.1 ± 3.1
Data are presented as n (%) or mean ± SD.
DM¼ diabetes mellitus; IPSS ¼ International Prostate Symptom Score; RH ¼ radical
hysterectomy; UDI-6 ¼ Urogenital Distress Inventory-6.
Fig. 1. Urethral overdilation using Hegar dilator. We dilated the urethra with Hegar
dilators progressively from Number 9 (27 Fr) to Number 18 (54 Fr).
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Study design
This was a retrospective study of the efﬁcacy of UOD in 36
women with voiding dysfunction. Between January 2005 and
December 2010, women with poor compliance and obstructive
symptoms registering high residual urine were enrolled in the
study. Three of 36 (8.3%) women had previous urethral dilation
diagnosed by other doctors. All the clinical data and video-
urodynamic studies (VUSs) results were recorded in a prospective
setting with the same protocol. The Institutional Review Board of
Chang-Gung Memorial Hospital, Tao-Yuan, Taiwan approved the
chart evaluation of this retrospective study.
The study protocol included the following. First, all patients
underwent a face-to-face structured interview that included
questions related to age, parity, medical illness, and previous sur-
gery. Drug history was also obtained to exclude a cause that may
aggravate the symptoms. Physical examination included height,
weight, and pelvic examination to detect the presence of pelvic
organ prolapse. Digital examination and pin prick test were per-
formed to assess the S2e4 dermatome. Patients with abnormal
neurological signs such as Babinski sign during pelvic examination
or unsteady gait were assessed for their underlying diseases. All
women in the study group had a baseline assessment including
urinalysis, post-void residual checked by ultrasonic bladder scan
(BVI 3000; Diagnostic Ultrasound Corporation, Bothell, WA, USA),
and a bladder diary. For better understanding of their self-
described response, women were asked to ﬁll out the Urogenital
Distress Inventory-6 (UDI-6) questionnaire and International
Prostate Symptom Score (IPSS) before and after treatment.
Second, in all cases only one physician (L.H.T.) performed the
VUS throughout the study period using the same protocol, which
complied with the guidelines of the International Continence So-
ciety [9], and all of the terms used in this study followed the
guidelines of the Society. A 4 F double lumen catheter (Medical
Measurement Systems, Enschede, The Netherlands) was inserted
into the bladder and a 10 F rectal catheter (Medtronic, Skovlunde,
Denmark) was inserted into the rectum. VUSs were performed
according to the standard protocol. Uroﬂowmetry and ﬁlling and
voiding cystometry were performed with a Dantec Menuet (Dantec
Medical A/S, Skovlunde, Denmark) multichannel urodynamic ma-
chine combined with a C-arm imaging system (GE OEC 7700). All
data were recorded and analyzed using the Dantec Menuet multi-
channel urodynamic machine (Dantec Medical A/S).
Patients' characteristics are shown in Table 1. Poor compliance
meant end-ﬁlling pressure > 20 cmH2O [10]. The normal range for
bladder compliance in adults has not been validated and previous
reports suggested the normal range should be 12.5e40.0mL/cmH2O
[11e13]. Instead of choosing volume/pressure change,we found that
end-ﬁlling detrusor pressurewas more practical for clinical use and
easy to read. This study adopted an end-ﬁlling detrusor pressure >
20 cmH2O to deﬁne poor bladder compliance; a cut-off commonly
observed in clinical practice [10]. High residual urinewas deﬁned as
> 100 mL [14]. UOD was performed only after medical treatment
failure, i.e., the patients had received a-1-blockers and/or anticho-
linergics, or physiotherapy for a 3-month period, but failed to
improve voiding efﬁcacy or compliance. All patients had a baseline
evaluation, including VUS and cystoscopy at the beginning of
treatment and6months later,with the intention to gauge the vesicle
pressure change and detect if urethra ﬁbrosis existed.
The technique of UOD was as follows. After obtaining adequate
general anesthesia, a 22 Fr panendoscopewas placed in the bladder
and the bladder and urethrawere inspectedwith right-angle lenses.
In each patient the bladder was distended to a capacity at 80 cmwater pressure, the volume was measured, the bladder was rein-
spected and distended for a second time to 80 cm water pressure,
and left for 5minutes. On this occasionwe intended to establish the
capacity and mucosal change. Usually, we left the bladder partially
full and then dilated the urethra with Hegar dilators progressively
from Number 9 (27 Fr) to Number 18 (54 Fr) (Fig. 1). The decision of
the ﬁnal size of the Hegar dilator (No. 18, 54 Fr.) was based on the
theory proposed by Turner-Warwick and Chapple [15], in which
they aimed to restore natural voiding by reducing the urethral
sphincter closing pressure by progressive stepwise recalibration.
Our goal was to dilate and stretch the urethra to its distensible
limits. At the completion of dilatation, we placed a 20 Fr catheter
into the bladder and a pack in the distal vagina to tamponade the
urethra. The procedurewas performed on an inpatient basis, and all
patients were taught clean intermittent catheterization preopera-
tively, and were instructed to perform self-catheterization if they
had any urinary retention after the procedures.
The subjective outcomes evaluation and quality of life assess-
ment including the use of UDI-6 questionnaire, and IPSS were
performed before and after treatment. Patients were reevaluated
every 3 months after UOD with free ﬂow rate plus ultrasound
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year. Medical records, videourodynamics evaluation, and cysto-
scopic ﬁndings were analyzed as the objective outcomes. Whether
UOD treatment was a success or failure depended on the change in
videourodynamic parameters, UDI-6 questionnaire, and IPSS.
Either subjective or objective outcome reaching statistical signiﬁ-
cance was regarded as success.
Statistical analysis
Values were given as mean ± standard deviation. All variables
were tested for normal distribution using the Kolmogor-
oveSmirnov test. Student t test was utilized to compare the means
of continuous variables and normally distributed data; otherwise,
the ManneWhitney U test was used. Categorical data were tested
by using the c2 test on the variables that evaluated differences
between groups as appropriate. The statistically signiﬁcant
(p < 0.05) variables from the univariate analysis were included in
multivariate analysis. The multivariate analysis was assessed by
multiple logistic regression based on forward data elimination. All
statistical tests were two-tailed and data were analyzed using SPSS
for Windows version 19.0 (SPSS Inc., Chicago, IL, USA).
Results
All 36 patients were followed up for amean 33.2 months (range:
13e61 months). The 36 women enrolled were divided into two
groups (Success vs. Failure). The mean age of the Success Group
(n ¼ 22, 61.1 %) and Failure Group (n ¼ 14, 38.9 %) was 52.8 years
and 54.3 years, respectively. The main indications, etiologies and
comparisons of demographic and clinical characteristics of the 36
women are given in Table 1. Patients due to poor compliance
comprised the majority of UOD cases. Etiology was neurogenic
(diabetes mellitus: 9 patients; stroke: 3 patients, 33.3%), continence
or prolapse surgery (5 patients, 13.8%), radical hysterectomy (14
patients, 38.8%) or hysterectomy alone (3 patients, 8.3%), and
idiopathic (2 patients, 5.5%).
Table 2 shows the comparisonof clinical characteristics afterUOD
among these subgroups in theSuccessGroup.Eighteenpatientswere
from poor compliance group and four from obstructive symptoms
group. Our data showed signiﬁcant improvements in mean UDI-6
score and IPSS after treatment (11.5e5.7, p ¼ 0.032 and 14.8e5.2,
p¼ 0.006, respectively). Changes in the other parameters, including
residual urine, end-ﬁlling pressure during videourodynamics, and
maximum cystometric capacity, were not statistically signiﬁcant.
We also analyzed multiple parameters (age, parity, body mass
index, videourodynamic parameters, anesthesia bladder capacity,
UDI-6 score, and IPSS) between the Success and Failure Groups, and
found only anesthesia bladder capacity reached statistical signiﬁ-
cance (536 mL vs. 418 mL, p ¼ 0.005; data not shown). None of our
patients had urethral perforation or prolonged bleeding during the
procedure. Incontinence, however, is a rare complication. It affected
three (8.3%) of the patients and most cases were transient.Table 2
Comparison of clinical characteristics after urethral overdilation in the Success
Group (n ¼ 22, 66.1%).
Before After p
Residual urine 115 ± 17.1 83 ± 15.4 0.051
End-ﬁlling pressure 24.1 ± 8.5 18.2 ± 7.3 0.563
Max. cystometric capacity 387.5 ± 11.9 401.3 ± 15.7 0.417
UDI-6 score 11.5 ± 2.4 5.7 ± 1.8 0.032
IPSS score 14.8 ± 2.1 5.2 ± 1.3 0.006
Data are presented as mean ± SD.
IPSS ¼ International Prostate Symptom Score; UDI-6 ¼ Urogenital Distress In-
ventory-6.Discussion
We have described the method of UOD (wide caliber), in which
the urethra was dilated up to 54 Fr in women with voiding
dysfunction. Our study indicated UOD could achieve 61.1% success,
and in addition, improve voiding efﬁcacy, bladder compliance, and
even relieve storage symptoms. L.K.L. has performedUOD since 1991,
and at least 200 patients have undergone the procedure, with 62.4%
reporting that it improved their symptoms signiﬁcantly (unpub-
lished data). These results prompted us to start the present study.
Urethral dilation to treat various disorders in women arose as
early as the 1920s with the aim of improving voiding symptoms
[16]. However, there was no available evidence or a well-designed
study to justify the efﬁcacy of urethral dilation. Thus, we con-
ducted this study to assess the long-term efﬁcacy of urethral dila-
tation. Contrary to prior knowledge, we propose threemechanisms.
(1) Adequate dilation size. Previous studies about the degree of
urethral dilation reported a variance from 18 Fr to 34 Fr, and mostly
they were performed on an outpatient basis with or without local
anesthesia. Under cystoscopic guidance, we left the bladder
partially full, and then dilated the urethra with Hegar dilators
progressively from Number 9 (27 Fr) to Number 18 (54 Fr). Our goal
was to dilate and stretch the urethra to its distensible limits.
Recently, Kiddoo et al [1] reported that urethral dilation (range:
18e36 Fr) was effective for lowering detrusor leak point pressure
and improving upper tract dilatation and vesicoureteral reﬂux. (2)
Satisfactory anesthesia level. Local anesthesia does not offer
adequate pain control during rigid cystoscopy in women [17]. Only
general anesthesia is sufﬁcient to provide pain relief so that effec-
tive dilation can be performed. (3) Revised dilationmechanism. Our
original aimwas to try wide-caliber dilation of the urethra and alter
the balance between detrusor power and bladder outlet resistance
[18]. However, the mechanism of urethral dilation is not only to
dilate the stenotic part, but also to restore the complex voiding
mechanism by reﬂex actions. The therapeutic efﬁcacy of urethral
dilation may have been due to modulation of the guarding reﬂex
[19]. Acute stretching of the external urethral sphincter may have
promoted the proliferation of local tissue or reorganization of
neural reﬂexes, resulting in a more sustained guarding reﬂex. Me-
chanical stretch is a potent regulator of tissue proliferation and
remodeling [19]. Previous reports showed not only a decrease in
the leak-point pressure, but also improved bladder compliance and
a reduction in uninhibited bladder contractions in patients with
neurogenic bladder [20]. Recently, Shaﬁk et al [21] also proposed
that mild urethral distention, which presumably occurs during the
passage of urine through the urethra, stimulates stretch receptors
in the urethral wall, leading reﬂexively to vesical contraction
(urethrovesical reﬂex).
Apparently, patients with poor compliance comprised the major
part of our patients. We chose patients with poor compliance
because theywere at high risk for upper urinary tract deterioration.
The underlying causes of voiding dysfunction in our patients
included neurogenic (12 patients, 33.3%; diabetes mellitus: 9 pa-
tients; stroke: 3 patients), continence or prolapse-related (5 pa-
tients, 13.8%), radical hysterectomy (14 patients, 38.8%) or
hysterectomy alone (3 patients, 8.3%), and idiopathic (2 patients,
5.5%). Most of our patients belonged to the neurogenic or radical-
hysterectomyerelated groups, but surprisingly, hysterectomy
accounted for ~8.3% of cases.
We knew about the long-term bladder dysfunction after radical
hysterectomy but some reports also mention the impact of hys-
terectomy on micturition or even urine retention [22,23]. The
reason for urine retention after hysterectomymight relate to undue
nerve damage, pre-existing pelvic ﬂoor dysfunction, or medication.
Thus de-innervation of the bladder and bladder neck, or de-
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retention after hysterectomy for benign disease.
Scarpero et al [24] have reported the correlation between the
degree of bother caused by lower urinary tract symptoms inwomen
and the degree of bother caused by symptoms correlated with
quality of life. They found that IPSS correlatedhighlywith the degree
of bother due to symptoms and that is the reasonwhy we used IPSS
for subjective assessment. If we compare the patient characteristics
between the Success and Failure Groups, then the only parameter
that tended towards signiﬁcance was anesthesia bladder capacity
(536 mL vs. 418 mL, p¼ 0.005). Previous thoughts about anesthesia
bladder capacity usually focus on patients with interstitial cystitis
and there was a strong inverse relationship between bladder ca-
pacity under anesthesia and disease severity (mean 845 mL with
Hunner's ulcer absent versus 531 mL when present) [25]. However,
during the surgical procedureswedid notﬁnd that anyone patient's
cystoscopic ﬁndings were compatible with interstitial cystitis. The
reason for the difference in anesthesia bladder capacity between the
Success and Failure Groups was not readily answered by what we
knew about the theory of interstitial cystitis. Patients with inter-
stitial cystitis and decreased anesthesia bladder capacity tend to
have more irritative storage symptoms rather than voiding prob-
lems. Therefore, we suggest a higher bladder capacity at the time of
hydrodistension is associated with a more intact micturition reﬂex,
which activates the voiding cycle, probably through a voluntary arc
involving reﬂex that coordinates relaxation of the urethra and with
sustained bladder contraction until emptying is complete. Based on
the Success Group, wewere unable to ﬁnd any causeeeffect relation
among the patients, which implied that the pathogenesis of voiding
dysfunction in women must be multifactorial.
Recently, the United States Food and Drug Administration (FDA)
has approved onabotulinum toxin A (Botox; Allergan, Irvine, CA,
USA) for treatment of urinary incontinence due to detrusor over-
activity associated with a neurological condition in adults who have
an inadequate response to or are intolerant of anticholinergic
medication. In addition, Schurch et al [26] conducted a prospective
study in 24 spinal cord injury patients and applied onabotulinum
toxin A as a treatment of detrusoresphincter dyssynergia in 1996.
With the same idea, Phelan et al [27] injected onabotulinum toxin A
into the urethral sphincter to restore bladder emptying in men and
womenwith voiding dysfunction in 2001, and achieved good results.
Onabotulinum toxin A might act through lowering the urethral
resistance or temporarily abolishing abnormal nerve response, to
improvevoidingefﬁcacy,whichmimics themechanismweproposed
for UOD. However, currently FDA has not approved BOTOX injection
formenorwomenwith voiding dysfunction. In addition, the FDAdid
not mention the efﬁcacy of BOTOX and the effect of BOTOX usually
only sustained for few months and patient have to pay for them-
selves. Therefore, the cost-effect of BOTOX remained controversial.
The strengths of our study include the uniform dilation size, the
prospective setting with the same protocol, assessment of patient-
oriented symptoms with validated questionnaires, a reasonable
follow-up period, and videourodynamic evaluation of all patients
before and after UOD. A potential limitation of the present studywas
the small number of patients, and it is worth noting that we focused
on this particular challenging group of patients with a high risk of
upper urinary tract damage, who failed to respond to conservative
treatment. Another limitation was the absence of a control group.
In conclusion, we report our experience in UOD for womenwith
voiding dysfunction. Contrary to previous reports, we propose three
unique steps ranging from adequate dilation size, to satisfactory
anesthesia level, and revised dilation mechanism. Overall, at least
61.1% of patients reported that UOD improved their symptoms
signiﬁcantly. As a minimally invasive procedure, UOD is a practical
method for treatment of women with voiding dysfunction,especially, as a bridge to connect between medications in vain and
pending further deﬁnitivemanagement. Nevertheless, these results
are preliminary and further studies are needed to substantiate the
clinical utility of these methods.Conﬂicts of interest
None.
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